Abstract:Schizophrenia is highly heritable and aggregating in families, but genetics alone does not exclusively explain the pathogenesis. Many risk factors, including childhood trauma, viral infections, migration, and the use of cannabis, are associated with schizophrenia. Adolescence seems to be the critical period where symptoms of the disease manifest. This work focuses on studying an epigenetic regulatory mechanism (the role of DNA methylation) and its interaction with mRNA expression during development, with a particular emphasis on adolescence. The presumptions regarding the role of aberrant neurodevelopment in schizophrenia were tested in the Methyl-Azoxy-Methanol (MAM) animal model. MAM treatment induces neurodevelopmental disruptions and behavioral deficits in off-springs of the treated animals reminiscent of those observed in schizophrenia and is thus considered a promising model for studying this pathology. On a gestational day-17, adult pregnant rats were treated with the antimitotic agent MAM. Experimental animals were divided into groups and subgroups according to substance treatment (MAM and vehicle agent [Sham]) and age of analysis (pre-adolescent and post-adolescent). Methylation and mRNA expression analysis of four candidate genes, which are often implicated in schizophrenia, with special emphasis on the Dopamine hypothesis i.e., Dopamine receptor D 2 ( Drd2 ), and the "co-factors" Disrupted in schizophrenia 1 ( DISC1 ), Synaptophysin ( Syp) , and Dystrobrevin-binding protein 1 ( Dtnbp1 ), was performed in the Gyrus cingulum (CING) and prefrontal cortex (PFC). Data were analyzed to observe the effect of substance treatment between groups and the impact of adolescence within-group. We found reduced pre-adolescent expression levels of Drd2 in both brain areas under the application of MAM. The "co-factor genes" did not show high deviations in mRNA expression levels but high alterations of methylation rates under the application of MAM (up to ~20%), which diminished in the further time course, reaching a comparable level like in Sham control animals after adolescence. The pre-adolescent reduction in DRD2 expression might be interpreted as downregulation of the receptor due to hyperdopaminergic signaling from the ventral tegmental area (VTA), eventually even to both investigated brain regions. The notable alterations of methylation rates in the three analyzed co-factor genes might be interpreted as attempt to compensate for the altered dopaminergic neurotransmission.

GAD1 alternative transcripts and DNA methylation in human prefrontal cortex and hippocampus in brain development, schizophrenia

Transcriptional Regulation of GAD1 GABA Synthesis Gene in the Prefrontal Cortex of Subjects with Schizophrenia

Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression

Comprehensive Analysis of Polymorphisms Throughout Gad1 Gene: A Family-Based Association Study in Schizophrenia

Conserved Chromosome 2q31 Conformations Are Associated With Transcriptional Regulation Of Gad1 Gaba Synthesis Enzyme And Altered In Prefrontal Cortex Of Subjects With Schizophrenia

Transcript-specific associations of SLC12A5 (KCC2) in human prefrontal cortex with development, schizophrenia, and affective disorders

Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia

Localization and Diagnostic Specificity of Glutamic Acid Decarboxylase Transcript Alterations in the Dorsolateral Prefrontal Cortex in Schizophrenia

Developmental and genetic regulation of the human cortex transcriptome illuminate schizophrenia pathogenesis

Transcriptomic analysis of postmortem brain identifies dysregulated splicing events in novel candidate genes for schizophrenia.

Single molecule in situ hybridization reveals distinct localizations of schizophrenia risk-related transcripts SNX19 and AS3MT in human brain

Genetic and Epigenetic Regulation on the Transcription of GABRB2: Genotype-dependent Hydroxymethylation and Methylation Alterations in Schizophrenia.

Genetic Dissection of Glutathione S-transferase Omega-1: Identification of Novel Downstream Targets and Alzheimer’s Disease Pathways

Association of GAD1 gene polymorphism rs3749034 with the information processing and cognitive event-related potentials in schizophrenia patients and healthy subjects

The genetics of schizophrenia: glutamate not dopamine?

Systematic study of association of four GABAergic genes: Glutamic acid decarboxylase 1 gene, glutamic acid decarboxylase 2 gene, GABAB receptor 1 gene and GABAA receptor subunit β2 gene, with schizophrenia using a universal DNA microarray

Methylation pattern and mRNA expression of synapse-relevant genes in the MAM model of schizophrenia in the time-course of adolescence

Profiling gene expression in the human dentate gyrus granule cell layer reveals insights into schizophrenia and its genetic risk

Transcriptional programs regulating neuronal differentiation are disrupted in DLG2 knockout human embryonic stem cells and enriched for schizophrenia and related disorders risk variants

Weak Association Between the Glutamate Decarboxylase 1 Gene (GAD1) and Schizophrenia in Han Chinese Population

Reduction of SynGAP-γ, disrupted splicing of , and oligodendrocyte deficits in mice, a genetic model of schizophrenia and neurodevelopmental disorder